Conciseness

The body is dense and operational — tool names, parameter corrections, fallback chains, thresholds — and avoids explaining concepts Claude already knows; the domain thresholds (pLI > 0.9, OpenTargets score > 0.7, Nelson et al. 2015) are genuinely additive. It is not a 5 because there is repetition: safety/pLI reasoning appears in the four-question framework, PATH 6, and the synthesis section, and retry logic appears inline despite being delegated to IMPLEMENTATION.md.

Actionability

Guidance is concrete and executable throughout: exact tool names per path, a working get_tool_info snippet, a table of parameter corrections ('takes `id` not `uniprot_id`'), named fallback chains, data minimums ('20 interactors OR documented explanation'), and explicit section-mapping for every path. It is not a 4 because the specific steps and parameters are given directly rather than left as high-level hints.

Workflow Clarity

The sequence is explicit and gated: identifier resolution first, PATH 0 before specialized paths, 'verify params BEFORE calling ANY tool for the first time', retry/fallback logic with 'NEVER silently skip failed tools', and a completeness audit checklist 'REQUIRED before finalizing'. These are explicit validation checkpoints with error-recovery feedback loops, matching the anchor-5 example's validate-fix-proceed pattern.

Progressive Disclosure

Structure matches the anchor-5 pattern — an overview body with well-signaled one-level-deep references (IMPLEMENTATION.md, EVIDENCE_GRADING.md, REPORT_FORMAT.md, REFERENCE.md, EXAMPLES.md) both inline and in a Reference Files table. It is not a 5 because some detail that is explicitly delegated to IMPLEMENTATION.md (retry logic, identifier resolution steps) is also duplicated inline, and the five referenced files were not present in the provided bundle, so the reference targets could not be verified.

Specificity

The description enumerates multiple concrete capability areas each anchored to specific data sources — 'tissue expression (GTEx, HPA), pathways, protein interactions (STRING), variant landscape (ClinVar, gnomAD), druggability (DGIdb, ChEMBL approved drugs)' plus method details ('9 parallel research paths with citations') — giving comprehensive, non-generic coverage. It is not a 4 because the coverage spans all the skill's major research dimensions rather than leaving minor gaps.

Completeness

It explicitly answers both questions: 'what' via the concrete capability list and 'when' via 'Use for full target profile reports, target characterization for drug discovery, and "tell me about target X" queries' with concrete trigger phrases. This matches the anchor-5 example pattern of capability list followed by an explicit 'Use when/for' clause.

Trigger Term Quality

Natural phrases users would say are present — 'full target profile reports', 'target characterization for drug discovery', "'tell me about target X' queries" — but common variations such as 'target validation', 'what do we know about target X', or 'gene target' are missing. It is above a 3 because keyword coverage is genuinely good with several natural phrasings, not just domain jargon.

Distinctiveness Conflict Risk

The drug-target intelligence niche is clear and the named databases (GTEx, HPA, STRING, ClinVar, gnomAD, DGIdb, ChEMBL) make it mostly distinct, but 'comprehensive ... research paths' phrasing leaves minor overlap risk with narrower single-database or general protein-analysis skills. Not a 5 because closely related bioinformatics skills could compete for some of the same queries.